SCHEMBL2651040

SCHEMBL2651040

Nc1ccc(OC(F)(F)F)c(C(=O)O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 4/20 0.50
MAPT P10636 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
HPGD P15428 3/20 0.50
THRB P10828 2/20 0.50
RECQL P46063 2/20 0.50
CYP3A4 P08684 2/20 0.50
HSD17B10 Q99714 2/20 0.50
POLB P06746 2/20 0.50
USP2 O75604 1/20 0.50
PKM P14618 1/20 0.50
APEX1 P27695 1/20 0.50
BLM P54132 1/20 0.50
MCL1 Q07820 1/20 0.50
TNF P01375 1/20 0.50
HSPD1 P10809 1/20 0.50
CYP2C9 P11712 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3947686 0.84 MCL1 (0.58) ALDH1A1KDM4EKMT2AMCL1AKR1C2
SCHEMBL4636514 0.83 ALDH1A1 (0.53) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL654962 0.82 GAA (0.53) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL29746555 0.81 KDM4E (0.50) KDM4EPOLBAPEX1KDREPHX2
SCHEMBL27051469 0.81 CA12 (0.50) ALDH1A1MAPTMEN1KMT2AHSD17B10
SCHEMBL21518046 0.81 KEAP1 (0.50) PKMEPHX2AKR1C2AKR1C1RXRA
SCHEMBL29646307 0.81 KEAP1 (0.50) PKMEPHX2AKR1C2AKR1C1RXRA
SCHEMBL2711853 0.81 KDM4E (0.50) KDM4EPOLBAPEX1KDREPHX2
SCHEMBL711924 0.80 KDM4E (0.59) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL1505290 0.79 EPHX2 (0.41) ALDH1A1KDM4EHPGDHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551793-B1 TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME AMKOR PHARMA INC (US) 2016-01-20 EP disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
US-7511074-B2 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same AMKOR PHARMA, INC. (US) 2009-03-31 US disclosed
US-20080227859-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same AMKOR PHARMA, INC. (US) 2008-09-18 US disclosed
US-7371896-B2 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same AMKOR PHARMA, INC. (US) 2008-05-13 US disclosed
US-7319160-B2 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same AMKOR PHARMA, INC. (US) 2008-01-15 US disclosed
US-20070078183-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same NEUROTECH CO., LTD. (KR) 2007-04-05 US disclosed
EP-1551793-A4 TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME NEUROTECH CO LTD (KR) 2007-04-04 EP disclosed
US-7189878-B2 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same NEUROTECH CO., LTD. (KR) 2007-03-13 US disclosed
US-20060235239-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same NEUROTECH CO., LTD. (KR) 2006-10-19 US disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 US disclosed
US-6927303-B2 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same NEUROTECH CO., LTD. (KR) 2005-08-09 US disclosed
EP-1551793-A1 TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME Neurotech Co., Ltd. (KR) 2005-07-13 EP disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-20040209957-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2004-10-21 US disclosed
WO-2004000786-A1 TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME NEUROTECH CO., LTD. (KR) 2003-12-31 WO disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed
EP-1183229-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-03-06 EP disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078183-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same HTT, BDNF, APP ALDH1A1 1111/4885KDM4E 3670/4885MAPT 12/4885
US-20080227859-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same HTT, BDNF, APP ALDH1A1 1111/4885KDM4E 3670/4885MAPT 12/4885
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR ALDH1A1 3968/4885KDM4E 3664/4885MAPT 4379/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR ALDH1A1 3968/4885KDM4E 3664/4885MAPT 4379/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR ALDH1A1 3968/4885KDM4E 3664/4885MAPT 4379/4885
US-20060235239-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same HTT, BDNF, APP ALDH1A1 1111/4885KDM4E 3670/4885MAPT 12/4885
US-20040209957-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same HTT, BDNF, APP ALDH1A1 1111/4885KDM4E 3670/4885MAPT 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.